Comparative Pharmacology
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus FLURBIPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOPROFEN CALCIUM versus FLURBIPROFEN SODIUM.
FENOPROFEN CALCIUM vs FLURBIPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Category C
Category D/X
NSAID
NSAID